New combo aims to slow aggressive lung cancer in the liver

NCT ID NCT05588388

First seen Nov 17, 2025 · Last updated May 15, 2026 · Updated 25 times

Summary

This study tests whether adding the drug bevacizumab to standard chemo-immunotherapy can help people with advanced small cell lung cancer that has spread to the liver. About 39 participants will receive the combination for four cycles, then continue on two maintenance drugs for up to a year. The goal is to see if the cancer stays stable longer and to check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

    RECRUITING

    Los Angeles, California, 90048, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact

    Contact Email: •••••@•••••

    Contact

  • V.A. Ann Arbor Healthcare System

    RECRUITING

    Ann Arbor, Michigan, 48105, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.